LUNAC Therapeutics raises £2.7m in Series A funding led by Epidarex Capital and University of Leeds to develop novel anticoagulants.
Epidarex Capital and the University of Leeds led the Series A round to support the development of next generation anticoagulants.
LUNAC Therapeutics is a drug discovery company developing next generation anticoagulants designed to minimise bleeding risk. The firm emerged as a spin out from the University of Leeds.
LUNAC Therapeutics has secured £2.7m in the first close of its Series A financing round. The investment was led jointly by Epidarex Capital and the University of Leeds.
The capital will support the company as it advances its discovery of novel anticoagulants aimed at reducing bleeding risks by targeting Factor XII. This work builds upon a decade of academic research conducted at the University of Leeds.
Previous academic work underpinning the company has received financial backing from the Wellcome Trust, the British Heart Foundation, and the Medical Research Council.
From the founder
"There is an urgent need for anticoagulant therapies with reduced bleeding risk. Our research has validated that targeting activated Factor XII may lead to differentiated therapies and a new treatment option for patients."
Helen Philippou
Scientific Founder at LUNAC Therapeutics
Investor perspective
"LUNAC is taking a unique approach to the identification of novel anticoagulants, and we have been very impressed by the progress of the Factor XII program at the University of Leeds. This investment builds on Epidarex’s track record of funding innovative spin-outs from leading research universities, both across the UK and in the US."
Mary Canning
Epidarex Capital
Investors
Categories
About the company
LUNAC Therapeutics
LUNAC Therapeutics develops advanced anticoagulants targeting activated Factor XII.